Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. What To Know: Johnson & Johnson on Monday entered into a ...
Intra-Cellular Therapies, Inc. reported that CAPLYTA's net product sales reached $199.2 million in the fourth quarter of 2024, a significant 51% increase compared to the previous year, contributing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results